Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VNN1 | O95497 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | GPR183 | P32249 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2377946 | 1.00 | VNN1 (0.46) | VNN1USP2SMN1; SMN2CTSKCYP11B2 | |
| SCHEMBL28604412 | 1.00 | VNN1 (0.46) | VNN1USP2SMN1; SMN2CTSKCYP11B2 | |
| SCHEMBL22078891 | 0.91 | MEN1 (0.44) | VNN1USP2SMN1; SMN2CTSKCYP11B2 | |
| SCHEMBL1118226 | 0.90 | USP2 (0.49) | VNN1USP2SMN1; SMN2CTSKMEN1 | |
| SCHEMBL1706650 | 0.87 | USP2 (0.43) | VNN1USP2SMN1; SMN2CTSKMEN1 | |
| SCHEMBL22088545 | 0.84 | USP2 (0.42) | USP2SMN1; SMN2CTSKCYP11B2MEN1 | |
| SCHEMBL22983897 | 0.84 | USP2 (0.42) | USP2SMN1; SMN2CTSKCYP11B2MEN1 | |
| SCHEMBL22983705 | 0.84 | USP2 (0.42) | USP2SMN1; SMN2CTSKCYP11B2MEN1 | |
| SCHEMBL30922631 | 0.81 | USP2 (0.55) | USP2SMN1; SMN2CTSKCYP11B2MEN1 | |
| SCHEMBL2378427 | 0.81 | USP2 (0.42) | USP2SMN1; SMN2CTSKCYP11B2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12358910-B2 | Heteroaromatic compounds as Vanin inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-07-15 | — | — | US | disclosed |
| CN-113166117-B | Heteroaromatic compounds as VANIN inhibitors | 勃林格殷格翰国际公司 | 2025-04-15 | — | — | CN | disclosed |
| US-12240828-B2 | Heteroaromatic compounds as vanin inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-03-04 | — | — | US | disclosed |
| EP-3890828-B1 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2025-02-19 | — | — | EP | disclosed |
| CN-113226462-B | Heteroaromatic compounds as VANIN inhibitors | 勃林格殷格翰国际公司 | 2025-02-11 | — | — | CN | disclosed |
| CN-114478485-B | Heteroaromatic compounds as VANIN inhibitors | 勃林格殷格翰国际有限公司 | 2024-04-05 | — | — | CN | disclosed |
| US-20230295112-A1 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2023-09-21 | — | — | US | disclosed |
| EP-3891142-B1 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2022-09-14 | — | — | EP | disclosed |
| CN-114478485-A | Heteroaromatic compounds as VANIN inhibitors | 勃林格殷格翰国际有限公司 | 2022-05-13 | — | — | CN | disclosed |
| US-20220048889-A1 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-02-17 | — | — | US | disclosed |
| CN-113226462-A | Heteroaromatic compounds as VANIN inhibitors | 勃林格殷格翰国际公司 | 2021-08-06 | — | — | CN | disclosed |
| CN-113166117-A | Heteroaromatic compounds as VANIN inhibitors | 勃林格殷格翰国际公司 | 2021-07-23 | — | — | CN | disclosed |
| CN-113166104-A | Heteroaromatic compounds as VANIN inhibitors | 勃林格殷格翰国际有限公司 | 2021-07-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12240828-B2 | Heteroaromatic compounds as vanin inhibitors | VHL, FANCI, PAH | VNN1 23/4885USP2 3663/4885SMN1; SMN2 3647/4885 |
| US-12358910-B2 | Heteroaromatic compounds as Vanin inhibitors | VHL, FANCI, PAH | VNN1 23/4885USP2 3663/4885SMN1; SMN2 3647/4885 |
| US-20230295112-A1 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | VHL, FANCI, PAH | VNN1 23/4885USP2 3663/4885SMN1; SMN2 3647/4885 |
| US-20220048889-A1 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | VHL, FANCI, PAH | VNN1 23/4885USP2 3663/4885SMN1; SMN2 3647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.